1. Home
  2. Approved trials
  3. » فارسی

Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg tablet manufactured by Actover Co. versus originator brand in healthy volunteers in fasting condition

Protocol summary

Study aim
Bioequivalence Study of Empagliflozin/Linagliptin 25/5 mg tablet (Glypover 25/5)manufactured by Actover Co. versus originator brand (Glyxambi) manufactured by Boehringer company
Design
Bioequivalence study, crossover, single-blinded, 24 healthy volunteers. Simple randomization was used for randomization
Settings and conduct
The study is a single-blinded, cross-over and fasting, and on two series of healthy volunteers. The study will be done in Tabriz, in Radin laboratory in two (96h) periods. The interval between these two periods is 5 weeks. In the first round of the study, the candidates are divided into two groups and the first group receives a test tablet and the second group receives a brand tablet. Blood samples are collected immediately before and after drug administration by volunteers. Then, drug extraction is done and samples are ready for analysis.
Participants/Inclusion and exclusion criteria
Inclusion Criteria: General Health (Liver, Heart, and Kidney), Body Mass Index (18-28), Informed consent, Age (18-55 years old) Exclusion criteria: Smoking, History of cardiovascular disease, History of liver and kidney disease, Alcoholism and Narcoticism, History of allergy to Empagliflozin/Linagliptin
Intervention groups
Intervention group 1: Glyxambi 25/5 mg tablet as a reference Intervention group 2: Glypover 25/5 mg manufactured by Actover Co. as a test
Main outcome variables
Maximum drug concentration, Time to reach maximum drug concentration

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20200623047902N36
Registration date: 2024-01-26, 1402/11/06
Registration timing: prospective

Last update: 2024-01-26, 1402/11/06
Update count: 0
Registration date
2024-01-26, 1402/11/06
Registrant information
Name
Elham Ghasemian
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 6696 5196
Email address
ghasemian@zistdaru.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2024-02-20, 1402/12/01
Expected recruitment end date
2025-02-19, 1403/12/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg tablet manufactured by Actover Co. versus originator brand in healthy volunteers in fasting condition
Public title
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg tablet
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
General Health (Liver, Heart, and Kidney) Body Mass Index (18-28) Informed consent Age (18-55 years old)
Exclusion criteria:
Smoking History of cardiovascular disease History of liver and kidney disease Alcoholism and Narcoticism History of allergy to Empagliflozin/Linagliptin
Age
From 18 years old to 55 years old
Gender
Both
Phase
Bioequivalence
Groups that have been masked
  • Participant
Sample size
Target sample size: 24
Randomization (investigator's opinion)
Randomized
Randomization description
People in the mentioned age group are invited to participate through the advertisement. People are then checked for health and healthy volunteers are identified. Each candidate is assigned a number from 1 to 24. The numbers are written on a plastic ball and poured into a container and mixed. The balls are then removed randomly from the container. The first 12 no.s are considered as (first sequence: Actover Co.'s medicine ) and the second 12 no.s are considered as (second sequence: originator brand recipient). The volunteers don't have any information about taking the test drug or brand drug
Blinding (investigator's opinion)
Single blinded
Blinding description
This study is a single-blinded clinical trial (volunteers). Test and Originator brand's tablets are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Research Ethics Committees of Tabriz University of Medical Sciences
Street address
Research and technology deputy,3rd floor, No 2 Central Building, Tabriz University of Medical Sciences, Golgasht Street
City
Tabriz
Province
Tehran
Postal code
5165665931
Approval date
2024-01-14, 1402/10/24
Ethics committee reference number
IR.TBZMED.REC.1402.797

Health conditions studied

1

Description of health condition studied
This study is performed on healthy volunteers and drug concentration in whole blood is determined.
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Drug concentration in plasma
Timepoint
pre-dose, 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 12.0, 24.0, 36.0, 48.0, 72.0 and 96.0 h after drug administration
Method of measurement
Liquid chromatography-MASS-MASS (LC- Mas/Mas)

Secondary outcomes

1

Description
Time to reach maximum drug concentration in plasma
Timepoint
After intervention
Method of measurement
Time to reach the maximum drug concentration is recorded.

2

Description
Extent of drug absorption
Timepoint
After intervention
Method of measurement
Calculation of area under curve of concentration -time

Intervention groups

1

Description
Intervention group: single dose, one oral tablet Glyxambi 25/5mg manufactured by Boehringer as a reference product. after the washout period, the volunteers receive Glypover 25/5mg tablet manufactured by Actover Co.
Category
Treatment - Drugs

2

Description
Intervention group: Single dose, Glypover 25/5mg tablet manufactured by Actover Co. as a test product. after the washout period, the volunteers receive Glyxambi 25/5 mg manufactured by Boehringer.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Radin laboratory
Full name of responsible person
Javad Shokri
Street address
No.22, first floor, Moalem st., Abureihan St
City
Tabriz
Province
East Azarbaijan
Postal code
5154995671
Phone
+98 914 313 5843
Email
Shokri.j@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Actover Co.
Full name of responsible person
Reza Karimi
Street address
No. 58, 8th St, Gisha
City
Tehran
Province
Tehran
Postal code
1446863914
Phone
+98 26 3476 0314
Email
info@actoverco.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Actover Co.
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Islamic Azad University
Full name of responsible person
Elham Ghasemian
Position
Visiting professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Islamic Azad university of Damghan, Cheshme Ali bolivar, Saadi square
City
Damghan
Province
Semnan
Postal code
3671637856
Phone
+98 23 3522 5046
Fax
Email
Ghasemian_elham@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Islamic Azad University
Full name of responsible person
Elham Ghasemian
Position
Visiting professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Islamic Azad university of Damghan, Cheshme Ali bolivar, Saadi square
City
Damghan
Province
Semnan
Postal code
3671637856
Phone
+98 23 3522 5046
Fax
Email
Ghasemian_elham@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Islamic Azad University
Full name of responsible person
Elham Ghasemian
Position
Visiting professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Islamic Azad university of Damghan, Cheshme Ali bolivar, Saadi square
City
Damghan
Province
Semnan
Postal code
3671637856
Phone
+98 23 3522 5046
Fax
Email
Ghasemian_elham@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
These data are as secure between researchers and related industries.
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Loading...